Stock Analiz

Edwards Lifesciences Corp (EW) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Edwards Lifesciences’s revenue went from $3.0B in fiscal 2016 to $6.1B in fiscal 2025, growth of about 8.3% a year.

Net income in fiscal 2025 was $1.1B, a net margin of 17.7%; the best year in this period was 2024 with $4.2B.

Over the twelve months to September 30, 2026, revenue was $6.7B and net income $1.0B.

Free cash flow was $1.3B in fiscal 2025 and positive in 10 of the 10 years shown.

The diluted share count fell 10% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $3.0B162017: $3.4B172018: $3.7B182019: $4.3B192020: $4.4B202021: $5.2B212022: $4.5B222023: $5.0B232024: $5.4B242025: $6.1B25$6.1B
Net income
2016: $570M162017: $584M172018: $722M182019: $1.0B192020: $823M202021: $1.5B212022: $1.5B222023: $1.4B232024: $4.2B242025: $1.1B25$1.1B
Free cash flow
2016: $528M162017: $833M172018: $688M182019: $928M192020: $647M202021: $1.4B212022: $974M222023: $643M232024: $290M242025: $1.3B25$1.3B
EPS (diluted)
2016: $0.87162017: $0.90172018: $1.13182019: $1.64192020: $1.30202021: $2.38212022: $2.44222023: $2.30232024: $6.97242025: $1.8325$1.83

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$6.7B$6.1B$5.4B$5.0B$4.5B$5.2B$4.4B$4.3B$3.7B$3.4B$3.0B
Gross profit$5.2B$4.7B$4.3B$4.0B$3.7B$4.0B$3.3B$3.2B$2.8B$2.6B$2.2B
Operating income$1.4B$1.3B$1.4B$1.3B$1.5B$1.7B$898M$1.1B$748M$1.1B$751M
Net income$1.0B$1.1B$4.2B$1.4B$1.5B$1.5B$823M$1.0B$722M$584M$570M
EPS (diluted)$1.77$1.83$6.97$2.30$2.44$2.38$1.30$1.64$1.13$0.90$0.87
R&D$1.1B$1.1B$1.1B$963M$844M$903M$761M$753M$622M$553M$442M
Revenue growth—+11.6%+8.6%+12.2%−14.7%+19.3%+0.9%+16.8%+8.4%+15.9%+18.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.7B$1.6B$542M$896M$1.2B$1.7B$1.1B$1.2B$927M$1.0B$704M
Capital spending-$293M-$260M-$252M-$253M-$245M-$326M-$407M-$254M-$239M-$168M-$176M
Free cash flow$1.4B$1.3B$290M$643M$974M$1.4B$647M$928M$688M$833M$528M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$755M$893M$1.2B$880M$1.7B$513M$625M$263M$796M$763M$662M
Stock-based pay$173M$158M$162M$139M$127M$109M$93M$81M$71M$62M$57M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$4.2B$4.0B$1.6B$1.2B$1.5B$1.4B$1.5B$956M$1.3B$1.3B
Debt—$705M$700M$685M$691M$690M$695M$679M$600M$1.0B$825M
Equity—$10.3B$10.0B$6.7B$5.8B$5.8B$4.6B$4.1B$3.1B$3.0B$2.6B
Total assets—$13.7B$13.1B$9.4B$8.3B$8.5B$7.2B$6.5B$5.3B$5.7B$4.5B
Shares (diluted)578M586M599M609M624M631M632M637M641M648M654M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin78.0%78.0%79.5%80.5%83.8%76.1%75.4%74.4%74.8%74.5%73.1%
Operating margin21.6%20.8%25.4%26.1%33.6%32.3%20.5%26.4%20.1%31.7%25.4%
Net margin15.3%17.7%76.8%28.0%34.1%28.7%18.8%24.1%19.4%17.0%19.2%
FCF margin21.3%22.0%5.3%12.8%21.8%26.9%14.8%21.3%18.5%24.2%17.8%
ROIC—9.5%11.6%15.9%20.1%22.9%15.3%21.3%19.0%15.4%16.8%
ROE—10.4%41.8%21.1%26.2%25.8%18.0%25.2%23.0%19.7%21.7%

Frequently asked questions

What is Edwards Lifesciences’s annual revenue?

$6.1B in fiscal 2025 and $6.7B over the twelve months to September 30, 2026.

How much profit does Edwards Lifesciences make?

Net income was $1.1B in fiscal 2025 (net margin 17.7%).

Is Edwards Lifesciences’s revenue growing?

Yes: revenue rose 11.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.